Induced Tauopathy in a Novel 3D-Culture Model Mediates Neurodegenerative Processes: A Real-Time Study on Biochips

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Seidel, Diana ^a   Krinke, Dana ^a   Jahnke, Heinz Georg ^a   Hirche, Anika ^a   Kloß, Daniel ^a   Mack, Till G A ^b,c   Striggow, Frank ^b,c   Robitzki, Andrea ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b KeyNeurotek Pharmaceuticals AG   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BIOCHIP; CONTROLLED STUDY; CULTURE TECHNIQUE; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MONOLAYER CULTURE; NERVE CELL CULTURE; NERVE DEGENERATION; PROTEIN EXPRESSION; TAUOPATHY;

AGING; ALZHEIMER DISEASE; CULTURE TECHNIQUES; DIELECTRIC SPECTROSCOPY; FEMALE; HUMANS; MICROARRAY ANALYSIS; MIDDLE AGED; NERVE DEGENERATION; NEURONS; TAU PROTEINS; TAUOPATHIES;

EID: 84868687152     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049150     Document Type: Article

References (43)

1. Rodgers AB (2008) ALZHEIMER'S DISEASE Unraveling the Mystery. In: Aging NIoHNIo, editor. Silver Spring. 79.
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM, (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3: 186-191.
4. Ittner LM, Gotz J, (2011) Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12: 65-72.
5. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, et al. (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482: 216-220.
6. Mondragon-Rodriguez S, Perry G, Zhu X, Boehm J, (2012) Amyloid Beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy. Int J Alzheimers Dis 2012: 630182.
7. Sinha G, (2011) Peering inside Alzheimer's brains. Nat Biotechnol 29: 384-387.
8. Jahnke HG, Rothermel A, Sternberger I, Mack TG, Kurz RG, et al. (2009) An impedimetric microelectrode-based array sensor for label-free detection of tau hyperphosphorylation in human cells. Lab Chip 9: 1422-1428.
9. Loffler T, Flunkert S, Taub N, Schofield EL, Ward MA, et al. (2012) Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates. J Mol Neurosci 47: 192-203.
10. Bose A, Mouton-Liger F, Paquet C, Mazot P, Vigny M, et al. (2011) Modulation of tau phosphorylation by the kinase PKR: implications in Alzheimer's disease. Brain Pathol 21: 189-200.
11. Pickl M, Ries CH, (2009) Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28: 461-468.
12. Huh D, Hamilton GA, Ingber DE, (2011) From 3D cell culture to organs-on-chips. Trends Cell Biol 21: 745-754.
13. Agholme L, Lindstrom T, Kagedal K, Marcusson J, Hallbeck M, (2010) An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis 20: 1069-1082.
14. Gotz J, Gladbach A, Pennanen L, van Eersel J, Schild A, et al. (2010) Animal models reveal role for tau phosphorylation in human disease. Biochim Biophys Acta 1802: 860-871.
15. Hinners I, Hill A, Otto U, Michalsky A, Mack TG, et al. (2008) Tau kinase inhibitors protect hippocampal synapses despite of insoluble tau accumulation. Mol Cell Neurosci 37: 559-567.
16. Krinke D, Jahnke HG, Mack TG, Hirche A, Striggow F, et al. (2010) A novel organotypic tauopathy model on a new microcavity chip for bioelectronic label-free and real time monitoring. Biosens Bioelectron 26: 162-168.
17. Leuba G, Walzer C, Vernay A, Carnal B, Kraftsik R, et al. (2008) Postsynaptic density protein PSD-95 expression in Alzheimer's disease and okadaic acid induced neuritic retraction. Neurobiol Dis 30: 408-419.
18. Zhang Z, Simpkins JW, (2010) An okadaic acid-induced model of tauopathy and cognitive deficiency. Brain Res 1359: 233-246.
19. Krinke D, Jahnke HG, Panke O, Robitzki AA, (2009) A microelectrode-based sensor for label-free in vitro detection of ischemic effects on cardiomyocytes. Biosens Bioelectron 24: 2798-2803.
20. Kloss D, Kurz R, Jahnke HG, Fischer M, Rothermel A, et al. (2008) Microcavity array (MCA)-based biosensor chip for functional drug screening of 3D tissue models. Biosens Bioelectron 23: 1473-1480.
21. Luo W, Dou F, Rodina A, Chip S, Kim J, et al. (2007) Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci U S A 104: 9511-9516.
22. Brunden KR, Trojanowski JQ, Lee VM, (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8: 783-793.
23. Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, et al. (2006) HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 20: 753-755.
24. Brunden KR, Ballatore C, Crowe A, Smith AB 3rd, Lee VM, et al (2010) Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 223: 304-310.
25. Zhao H, Michaelis ML, Blagg BS, (2012) Hsp90 modulation for the treatment of Alzheimer's disease. Adv Pharmacol 64: 1-25.
26. Wischik C, Staff R, (2009) Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging 13: 367-369.
27. Jalava A, Akerman K, Heikkila J, (1993) Protein kinase inhibitor, staurosporine, induces a mature neuronal phenotype in SH-SY5Y human neuroblastoma cells through an alpha-, beta-, and zeta-protein kinase C-independent pathway. J Cell Physiol 155: 301-312.
28. Mikami M, Goubaeva F, Song JH, Lee HT, Yang J, (2008) beta-Adrenoceptor blockers protect against staurosporine-induced apoptosis in SH-SY5Y neuroblastoma cells. Eur J Pharmacol 589: 14-21.
29. Cheung YT, Lau WK, Yu MS, Lai CS, Yeung SC, et al. (2009) Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 30: 127-135.
30. Rothermel A, Biedermann T, Weigel W, Kurz R, Ruffer M, et al. (2005) Artificial design of three-dimensional retina-like tissue from dissociated cells of the mammalian retina by rotation-mediated cell aggregation. Tissue Eng 11: 1749-1756.
31. Guo JL, Lee VM, (2011) Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 286: 15317-15331.
32. Jeganathan S, Hascher A, Chinnathambi S, Biernat J, Mandelkow EM, et al. (2008) Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. J Biol Chem 283: 32066-32076.
33. Iovino M, Patani R, Watts C, Chandran S, Spillantini MG, (2010) Human stem cell-derived neurons: a system to study human tau function and dysfunction. PLoS One 5: e13947.
34. Hubinger G, Geis S, LeCorre S, Muhlbacher S, Gordon S, et al. (2008) Inhibition of PHF-like tau hyperphosphorylation in SH-SY5Y cells and rat brain slices by K252a. J Alzheimers Dis 13: 281-294.
35. Julien C, Bretteville A, Planel E, (2012) Biochemical isolation of insoluble tau in transgenic mouse models of tauopathies. Methods Mol Biol 849: 473-491.
36. Lim J, Balastik M, Lee TH, Nakamura K, Liou YC, et al. (2008) Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J Clin Invest 118: 1877-1889.
37. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
38. Justice BA, Badr NA, Felder RA, (2009) 3D cell culture opens new dimensions in cell-based assays. Drug Discov Today 14: 102-107.
39. Silveyra MX, Garcia-Ayllon MS, de Barreda EG, Small DH, Martinez S, et al. (2012) Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice. Neurobiol Aging 33: 624 e623-634.
40. Jahnke HG, Braesigk A, Mack TG, Ponick S, Striggow F, et al. (2011) Impedance spectroscopy based measurement system for quantitative and label-free real-time monitoring of tauopathy in hippocampal slice cultures. Biosens Bioelectron.
41. Zhang XM, Cai Y, Xiong K, Cai H, Luo XG, et al. (2009) Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur J Neurosci 30: 2271-2283.
42. Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, et al. (2010) Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem 285: 30851-30860.
43. Avila J, (2010) Alzheimer disease: caspases first. Nat Rev Neurol 6: 587-588.